SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow -2.1% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.75M | — | $29.01M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.24M | +0.3% | $13.07M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.24M | +0.3% | $13.07M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Millennium Management ✦ | 939.28K | +93.0% | $9.91M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 805.46K | +219.0% | $8.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 805.46K | +219.0% | $8.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 163.25K | +0.6% | $1.72M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 163.25K | +0.6% | $1.72M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 98.08K | -54.2% | $1.03M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 76.73K | -4.7% | $809,522 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 76.73K | -4.7% | $809,522 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Marshall Wace ✦ | 52.91K | -32.1% | $558,159 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 52.91K | -32.1% | $558,159 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 19.92K | -95.7% | $211,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Duquesne Family Office | $7.79M | was 0.3% |
| Renaissance Technologies | $229,100 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 201 holders, 92.94M shares, $730.00M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.